![]() Written informed consent was obtained from all patients. This study was approved by the Blood Diseases Hospital in compliance with the Declaration of Helsinki. This study is based upon data from the National Longitudinal Cohort of Hematological Diseases in China (NCT04645199) in brief, it is a large-scale prospective cohort study that set out to analyze the incidence and risk factors associated with hematologic diseases, in addition to the treatment options and prognosis for these patients in China. Subsequent prospective trials are essential to validate these observations. ![]() Our study revealed the enhanced clinical significance of ASCT in patients with transplant-eligible myeloma, regardless of early MRD status, particularly for high-risk patients. In addition, we identified four MRD-status transformation patterns following ASCT, which were strongly correlated with diverse survival outcomes ( P < 0.001). Similar results were observed in patients with detectable MRD after induction treatment. These clinical benefits were more pronounced in patients with aggressive features (high-risk cytogenetic abnormalities or high tumor burden) compared with standard-risk patients. Of note, patients who achieved undetectable MRD early still benefitted from ASCT, with a remarkable improvement in the median MRD-negative duration (33.5–58.0 months, P < 0.001), progression-free survival (PFS 46.0–88.3 months, P < 0.001), and overall survival (OS 76.4 months to not reached, P = 0.003). Early MRD-negative status was associated with a lower risk of disease progression and death (HR = 0.473 95% CI, 0.320–0.700 P < 0.001). The current study included 407 patients with transplant-eligible multiple myeloma with available MRD status from the National Longitudinal Cohort of Hematological Diseases in China (NCT04645199), of whom 147 (34.4%) achieved early undetectable MRD and 182 (44.7%) received ASCT. But there is a current lack of data regarding the clinical benefit of autologous stem cell transplantation (ASCT) for patients with myeloma achieving early MRD-negative status after induction treatment, in addition to the interaction of longitudinal MRD status with ASCT. You'll meet with your care team frequently to watch for side effects and to monitor your body's response to the transplant.Attaining undetectable minimal residual disease (MRD) is the current therapeutic goal for multiple myeloma. Your stem cells will be infused into your bloodstream, where they will travel to your bone marrow and begin creating new blood cells.Īfter your autologous stem cell transplant, you'll remain under close medical care. Talk with your doctor about what you can expect from your treatment. The cancer treatments used during the conditioning process carry a risk of side effects. The treatments you undergo depend on your disease and your particular situation. ![]() During the conditioning process, you'll receive high doses of chemotherapy or radiation therapy - or sometimes both treatments - to kill your cancer cells. Undergoing high doses of cancer treatment (conditioning). A machine filters out the stem cells and the rest of your blood is returned to your body.Ī preservative is added to your stem cells and then they're frozen and stored for later use. For stem cell collection, a needle is inserted into a vein in your arm to draw out your blood. You'll receive medications that cause your stem cells to increase in number and to move out of your bone marrow and into your blood, where they can be easily collected.įiltering stem cells from your blood. Taking medications to increase the number of stem cells in your blood.Undergoing an autologous stem cell transplant involves: An autologous stem cell transplant helps to replace the damaged bone marrow.Īn autologous stem cell transplant is most often used to treat: These treatments are likely to damage the bone marrow. Autologous stem cell transplants are typically used in people who need to undergo high doses of chemotherapy and radiation to cure their diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |